Effect of Smoking on Activated Clotting Time Values During Coronarography and Angioplasty
NCT ID: NCT04897997
Last Updated: 2021-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2020-01-06
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Kinetics of C-Reactive Protein During the Management of Acute Coronary Syndrome Treated by Transluminal Angioplasty
NCT05233176
Validation/Evaluation of Multimodal Imaging Combining 3D Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease
NCT01321970
Platelet Indices in Patients Undergoing Primary PCI and Its Prognostic Value
NCT04290949
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NCT04604197
Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery
NCT01045850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study hypothesis was that the procoagulant effect of the tobacco may be responsible of reduced anticoagulation levels after standardized UFH administrations and thus presenting an UFH resistance requiring increased UFH dosages to obtain a therapeutic ACT values.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non smokers
never having smoked patients
coronarography and angioplasty
selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
smokers
actively smoking patients
coronarography and angioplasty
selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
acute coronary syndrome
patients with the coronary indication of ACS
coronarography and angioplasty
selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
stable
patients with the coronary indication of stable or silent ischemia
coronarography and angioplasty
selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
coronarography and angioplasty
selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any patient presenting with one of the following characteristic known to impact either on ACT or aPTT measurements as: oral anticoagulation medication (anti-vitamin K and non-vitamin K antagonist oral anticoagulants \[NOAC\]), fondaparinux or LMWH usage, coagulopathy defined as prothrombin time \< 50 % or thrombopenia \< 50 000 G/L, declared or observed thrombophilia defined as antithrombin \< 50%, baseline aPTT values with a ratio patient/control \> 1.2 presence of lupus anticoagulant, connective tissue disease, active cancer
* a person as defined by the law articles L. 1121-5, L. 1121-7 et L1121-8 of the Code de la santé publique, France (pregnant, parturient women or breastfeeding women, legally adult patient under legal protection measure \[tutelage, protection of vulnerable adults\]),
* a person as defined by the law articles L. 3212-1 et L. 3213-1 of the Code de la santé publique, France (legally adult patient unable to consent, person with legal or administrative freedom restriction or person under psychiatric treatment)
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr Camenzind
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edoardo Camenzind, Professor
Role: STUDY_DIRECTOR
University Hospital Nancy France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Nancy Brabois
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20210502VandoeuvreFranceEurope
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.